Innovative R&D Approach AQEMIA leverages cutting-edge quantum-inspired physics algorithms combined with generative AI to accelerate drug discovery, presenting opportunities to partner with pharmaceutical companies seeking to incorporate advanced computational methods into their pipelines.

Recent Funding & Expansion With over 100 million dollars in funding and recent office expansion into London, AQEMIA demonstrates strong growth momentum and a strategic push into international markets, making it a promising partner for organizations looking to collaborate on innovative biotech projects.

High-Impact Collaborations AQEMIA has a proven track record of successful drug discovery initiatives in collaboration with top pharmaceutical firms, suggesting ample opportunities for new partnerships to co-develop novel therapeutics utilizing their proprietary platform.

Emerging Market Presence Positioned within the French Tech 120 and operating across Paris and London, AQEMIA is well-placed to tap into European biotech investment trends and expand its client base with biotech and pharma partners seeking next-gen drug discovery solutions.

Technological Edge The company's use of advanced tech stacks such as TensorFlow, NoSQL, and quantum-inspired algorithms indicates a strong technological foundation, which can attract tech-driven pharma and biotech organizations interested in innovative computational platforms for drug development.